NCT03676322View on ClinicalTrials.gov

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

July 26, 2019

Study Completion Date

July 26, 2019

Conditions
Healthy
Interventions
DRUG

M5049

Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.

DRUG

Placebo

Participants will receive placebo matched to M5049.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03676322 - Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants | Biotech Hunter | Biotech Hunter